S Ciardullo, E Bianconi, R Cannistraci, P Parmeggiani, E M Marone, G Perseghin
{"title":"Peripheral artery disease and all-cause and cardiovascular mortality in patients with NAFLD.","authors":"S Ciardullo, E Bianconi, R Cannistraci, P Parmeggiani, E M Marone, G Perseghin","doi":"10.1007/s40618-022-01792-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Cardiovascular disease (CVD) is the first cause of death in patients with non-alcoholic fatty liver disease (NAFLD) and risk stratification is recommended by current guidelines. The aim of this study is to assess the prevalence of peripheral arterial disease (PAD) in patients with NAFLD and its association with all-cause and cardiovascular disease (CVD) mortality.</p><p><strong>Methods: </strong>9145 participants 40 years or older attended a mobile examination center visit in the 1999-2004 cycles of the National Health and Nutrition Examination Survey. PAD was defined as an ankle-brachial index (ABI) < 0.90 in either of the legs and mortality data through December 2015 were obtained from the National Death Index. NAFLD was defined by a fatty liver index ≥ 60 in the absence of other liver conditions, leading to a final sample of 3094 subjects.</p><p><strong>Results: </strong>The overall prevalence of PAD was 5.9% (95% CI 5.0-6.9). Over a median follow-up of 13 years, 876 participants died, 208 of cardiovascular causes. Incidence rates of all-cause mortality (for 1000 person-years) were 20.2 (95% CI 18.7-21.7) and 70.0 (95% CI 60.1-81.6) for participants without and with PAD, respectively. Multivariable-adjusted Cox proportional hazard models showed that PAD was associated with a higher risk of all-cause (1.8, 95% CI 1.4-2.4) and cardiovascular mortality (HR 2.5, 95% CI 1.5-4.3) after adjustment for potential confounders including prevalent CVD.</p><p><strong>Conclusion: </strong>Current guidelines strongly encourage the screening of CVD in patients with NAFLD and the use of the simple and inexpensive measurement of ABI in routine clinical practice may find indication.</p>","PeriodicalId":15651,"journal":{"name":"Journal of Endocrinological Investigation","volume":"45 1","pages":"1547-1553"},"PeriodicalIF":3.9000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270293/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Endocrinological Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40618-022-01792-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/4/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Cardiovascular disease (CVD) is the first cause of death in patients with non-alcoholic fatty liver disease (NAFLD) and risk stratification is recommended by current guidelines. The aim of this study is to assess the prevalence of peripheral arterial disease (PAD) in patients with NAFLD and its association with all-cause and cardiovascular disease (CVD) mortality.
Methods: 9145 participants 40 years or older attended a mobile examination center visit in the 1999-2004 cycles of the National Health and Nutrition Examination Survey. PAD was defined as an ankle-brachial index (ABI) < 0.90 in either of the legs and mortality data through December 2015 were obtained from the National Death Index. NAFLD was defined by a fatty liver index ≥ 60 in the absence of other liver conditions, leading to a final sample of 3094 subjects.
Results: The overall prevalence of PAD was 5.9% (95% CI 5.0-6.9). Over a median follow-up of 13 years, 876 participants died, 208 of cardiovascular causes. Incidence rates of all-cause mortality (for 1000 person-years) were 20.2 (95% CI 18.7-21.7) and 70.0 (95% CI 60.1-81.6) for participants without and with PAD, respectively. Multivariable-adjusted Cox proportional hazard models showed that PAD was associated with a higher risk of all-cause (1.8, 95% CI 1.4-2.4) and cardiovascular mortality (HR 2.5, 95% CI 1.5-4.3) after adjustment for potential confounders including prevalent CVD.
Conclusion: Current guidelines strongly encourage the screening of CVD in patients with NAFLD and the use of the simple and inexpensive measurement of ABI in routine clinical practice may find indication.
目的:心血管疾病(CVD)是非酒精性脂肪肝(NAFLD)患者的首要死因,现行指南建议对患者进行风险分层。本研究的目的是评估非酒精性脂肪肝患者中外周动脉疾病(PAD)的患病率及其与全因死亡率和心血管疾病(CVD)死亡率的关系。方法:9145 名 40 岁及以上的参与者参加了 1999-2004 年周期性全国健康与营养调查的流动检查中心访问。PAD的定义是踝肱指数(ABI)结果:PAD的总患病率为5.9%(95% CI为5.0-6.9)。在13年的中位随访中,876名参与者死亡,其中208人死于心血管疾病。无 PAD 和 PAD 患者的全因死亡率(千人年)分别为 20.2(95% CI 18.7-21.7)和 70.0(95% CI 60.1-81.6)。多变量调整后的考克斯比例危险模型显示,在调整了包括流行性心血管疾病在内的潜在混杂因素后,PAD与较高的全因死亡风险(1.8,95% CI 1.4-2.4)和心血管死亡风险(HR 2.5,95% CI 1.5-4.3)相关:结论:目前的指南大力鼓励对非酒精性脂肪肝患者进行心血管疾病筛查,在常规临床实践中使用简单、廉价的 ABI 测量方法可能会找到适应症。
期刊介绍:
The Journal of Endocrinological Investigation is a well-established, e-only endocrine journal founded 36 years ago in 1978. It is the official journal of the Italian Society of Endocrinology (SIE), established in 1964. Other Italian societies in the endocrinology and metabolism field are affiliated to the journal: Italian Society of Andrology and Sexual Medicine, Italian Society of Obesity, Italian Society of Pediatric Endocrinology and Diabetology, Clinical Endocrinologists’ Association, Thyroid Association, Endocrine Surgical Units Association, Italian Society of Pharmacology.